

Status: Currently Official on 18-Feb-2025
 Official Date: Official as of 01-Aug-2023
 Document Type: USP Monographs
 DocId: GUID-8D20062A-FAE5-4BA0-A68B-2013E06258B3_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M40423_04_01
 DOI Ref: uht5i

© 2025 USPC
 Do not distribute

Indomethacin Suppositories

DEFINITION

Indomethacin Suppositories contain NLT 90.0% and NMT 110.0% of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the indomethacin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: Prepare 0.1% of formic acid by diluting 1 mL of formic acid with water to 1 L.

Mobile phase: Acetonitrile and *Solution A* (45:55)

Diluent: *Mobile phase* adjusted with 0.2 M sodium hydroxide (NaOH) to a pH of 8.0

System suitability solution: 0.002 mg/mL of [USP Indomethacin RS](#), 0.002 mg/mL of [USP Indomethacin Related Compound A RS](#), and 0.01 mg/mL of [USP Indomethacin Related Compound B RS](#) in *Diluent*

Standard solution: 0.5 mg/mL of [USP Indomethacin RS](#) in *Diluent*. Sonicate if necessary.

Sample solution: Prepare a solution nominally equivalent to 0.5 mg/mL of indomethacin in *Diluent* as follows. Mash NLT 10 Suppositories in a beaker, and heat (at about 50°) on a water bath until melted. Mix well and cool. Transfer a portion of the mass equivalent to 10 mg of indomethacin into a 20-mL volumetric flask and add 10 mL of acetonitrile. Heat in a water bath at 50° to dissolve, and dilute with *Diluent* to volume.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: PDA (scan 200–600 nm). Calculations should be based on the chromatograms collected at 240 nm. For *Identification* test B, use spectra at the scanned range.

Column: 4.6-mm × 25-cm; 5-μm packing L1

Column temperature: 30°

Flow rate: 1.5 mL/min

Injection volume: 10 μL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 4 between indomethacin related compound A and indomethacin related compound B, *System suitability solution*

Tailing factor: NMT 1.5, *Standard solution*

Relative standard deviation: NMT 1.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$) in the portion of Suppositories taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Indomethacin RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of indomethacin in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

DISSOLUTION (711)

Medium: 0.1 M, pH 7.2 phosphate buffer (see [Reagents, Indicators, and Solutions—Buffer Solutions](#)); 900 mL



Documents

Document Sharing Hub

Apparatus 2: 50 rpm**Time:** 60 min**Standard solution:** [USP Indomethacin RS](#) at a known concentration in *Medium***Sample solution:** Proceed as directed for sample per [Dissolution \(711\)](#). Dilute with *Medium* as needed.**Instrumental conditions****Mode:** UV**Analytical wavelength:** 320 nm**Analysis****Samples:** *Standard solution* and *Sample solution***Tolerances:** NLT 75% (Q) of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$) is dissolved.**Change to read:**

- **UNIFORMITY OF DOSAGE UNITS (905):** ▲Meet the requirements▲ (CN 1-Aug-2023)

Diluent: Methanol and glacial acetic acid (199:1)**Standard solution:** 25 µg/mL of [USP Indomethacin RS](#) in *Diluent*

Sample solution: Place 1 Suppository into a 100-mL volumetric flask containing 80 mL of *Diluent*, shake by mechanical means until the Suppository is dissolved, and dilute with *Diluent* to volume. Filter a portion of the solution, discarding the first 15 mL of the filtrate, and dilute a volume of the clear filtrate with the *Diluent* to obtain a solution having a concentration of 25 µg/mL of indomethacin.

Instrumental conditions**Mode:** UV**Detector:** 320 nm**Blank:** *Diluent***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$) in the Suppository taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times 100$$

 A_U = absorbance of the *Sample solution* A_S = absorbance of the *Standard solution* C_S = concentration of [USP Indomethacin RS](#) in the *Standard solution* (µg/mL) C_U = nominal concentration of indomethacin in the *Sample solution* (µg/mL)

▲ (CN 1-Aug-2023)

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers at controlled room temperature.

- **USP REFERENCE STANDARDS (11).**

[USP Indomethacin RS](#)[USP Indomethacin Related Compound A RS](#)

5-Methoxy-2-methyl-3-indoleacetic acid.

 $C_{12}H_{13}NO_3$ 219.24[USP Indomethacin Related Compound B RS](#)

4-Chlorobenzoic acid.

 $C_7H_5ClO_2$ 156.57**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
INDOMETHACIN SUPPOSITORIES	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 50(6)

Current DocID: GUID-8D20062A-FAE5-4BA0-A68B-2013E06258B3_4_en-US